| Marijuana neurobiology and treatment. | |
| | |
MedLine Citation:
|
PMID: 19042204 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Marijuana is the number one illicit drug of abuse worldwide and a major public health problem, especially in the younger population. The objective of this article is to update and review the state of the science and treatments available for marijuana dependence based on a pre-meeting workshop that was presented at ISAM 2006. At the workshop, several papers were presented addressing the neurobiology and pharmacology of marijuana and treatment approaches, both psychotherapy and medications, for marijuana withdrawal. Medicolegal and ethical issues concerning marijuana medical use were also discussed. Concise summaries of these presentations are incorporated in this article, which is meant to be an updated review of the state of the science. Major advances have been made in understanding the underpinning of marijuana dependence and the role of the CNS cannabinoid system, which is a major area for targeting medications to treat marijuana withdrawal and dependence, as well as other addictions. Behavioral therapies are efficacious for facilitating abstinence from marijuana. Nefazadone, Marinol, and buspirone are showing early positive signals for efficacy in ameliorating marijuana withdrawal symptoms. Effective psychotherapeutic approaches are available and promising medications studies need to be confirmed in outpatient trials. The next few years looking promising for translational research efforts to make treatment widely accessible to patients with marijuana dependence. |
| | |
Authors:
|
Ahmed Elkashef; Frank Vocci; Marilyn Huestis; Margaret Haney; Alan Budney; Amanda Gruber; Nady el-Guebaly |
Related Documents
:
|
12171024 - Medical marijuana--is it safe? 22256244 - Lossless watermarking of categorical attributes for verifying medical data base integrity. 2406924 - Some implications for the study of the doctor-patient interaction: power, structure, an... 6955684 - The occupational hazards of leptospirosis in the meat industry. 18194914 - Antivenom therapy for crotaline snakebites: has the poison control center provided effe... 8311894 - Social responsibility and the academic medical center: building community-based systems... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse Volume: 29 ISSN: 0889-7077 ISO Abbreviation: Subst Abus Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-12-01 Completed Date: 2008-12-31 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 8808537 Medline TA: Subst Abus Country: United States |
Other Details:
|
Languages: eng Pagination: 17-29 Citation Subset: IM |
Affiliation:
|
Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA. ae8a@nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Brain
/
drug effects* Buspirone / therapeutic use* Cannabis / adverse effects* Cognitive Therapy Humans Marijuana Abuse / rehabilitation*, therapy Narcotic Antagonists / therapeutic use* Social Facilitation Tetrahydrocannabinol / therapeutic use* Triazoles / therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
NIH0010134921//PHS HHS |
| Chemical | |
Reg. No./Substance:
|
0/Narcotic Antagonists; 0/Triazoles; 1972-08-3/Tetrahydrocannabinol; 36505-84-7/Buspirone; 83366-66-9/nefazodone |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Medical consequences of drug abuse and co-occurring infections: research at the National Institute o...
Next Document: Pharmacotherapy of methamphetamine addiction: an update.